Laminar Pharma is Biotechnology in Spain that focus on initial clinical development business. Founded in 2006. They cover business area such as operator, discovery, rational design, initial clinical development, new MLT-base drug, next-generation medicine, nutraceutical and cosmetic product, membrane lipid, specific cellular protein, physician, class.
2006
( 20 years old in 2026 )
Initial Clinical Development
-
Ctra. de Valldemossa Km. 7,4, ParcBit
Calle Isaac Newton, Edificio Naorte Bloque A, 1ª planta, puerta 3
07121 Palma de Mallorca
Spain
Private
operatordiscoveryrational designinitial clinical developmentnew MLT-base drugnext-generation medicinenutraceutical and cosmetic productmembrane lipidspecific cellular proteinphysicianclass
* We use standard office opening hours in near Laminar Pharma's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Laminar Pharma is Biotechnology business from Spain that founded in 2006 (20 years old in 2026), Laminar Pharma business is focusing on Initial Clinical Development.
Laminar Pharma headquarter office and corporate office address is located in Ctra. de Valldemossa Km. 7,4, ParcBit Calle Isaac Newton, Edificio Naorte Bloque A, 1ª planta, puerta 3 07121 Palma de Mallorca Spain.
Laminar Pharma was founded in Spain.
In 2026, Laminar Pharma is currently focus on initial clinical development sector.
Above is snippet of Google Trends for "initial clinical development" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Laminar Pharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
